Join us for the Autoimmune Community Summit, October 21 & 22. It’s designed for patients, care partners, and advocates — it’s FREE and virtual!

Search Autoimmune Association
Share this article
Aardas Response To New York Times Editorial

AARDA’s Response to New York Times Editorial

How is it fair that patients with the most need may never benefit from new drugs that might never be manufactured?  Read AARDA’s response to a recent New York Times editorial stating that as a reasonable trade-off to reducing payments to drug companies, 8 to 15 drugs might not come to market. For too many people with chronic and debilitating conditions, serious illnesses, and disabilities, these new drugs could hold the life-changing medicine that they need to lead full and healthy lives.

How is it fair that patients with the most need may never benefit from new drugs that might never be manufactured?  This is a bitter, unfair solution for millions of people living with autoimmune disease and other conditions that have yet to benefit from a medicine developed and exponentially effective for them.

The Autoimmune Association is dismayed by a recent New York Times editorial, “The American Way of Paying for Drugs Isn’t Working,” stating that as a reasonable trade-off to reducing payments to drug companies, eight to fifteen drugs might not come to market.  For too many people with chronic and debilitating conditions, serious illnesses, and disabilities, these new drugs could hold the life-changing medicine that they need to lead full and healthy lives.

While CBO estimates that some 300 drugs would still come to market under this new model,  it is a risk that your breakthrough drug may be one that is deferred that falls disproportionately on people with rare, often multiple conditions. Every day, these Americans struggle against the devastating effects of their diseases – hoping that the pharmaceutical innovation pipeline will deliver a miracle.

People living with autoimmune diseases, like the majority of Americans, are alarmed at rising costs across the health care sector, and they, more than most, face growing barriers from unwarranted step therapy, utilization management, and contracting arrangements that fail to put patients’ first.  They have an enormous stake in continuing pharmaceutical innovation – not hindering it – to ensure improved health and wellness. These Americans, whose futures may depend on the cure or treatment inherent in one of those eight-to-fifteen drugs at risk of being sidelined, undiscovered and unrealized – should not have their health, their lives diminished or traded away as collateral damage in resolving America’s health care system. We can do better, together.

Randall Rutta

President & CEO

AARDA

Share this article

Join our email list

Receive the latest blog articles, news, and more right to your inbox!

Related articles you might be interested in

Am Addisons Disease Celiac Mom Story

Addison’s Disease & Celiac Mom Story: “The Autoimmune Snowball”

I was 32 years old.  I had just survived a miserable pregnancy and rough delivery, but instead of gaining my strength back and...
Am Addisons Disease

Addison’s Disease: Overview of Antibodies & Genetic Links

Addison’s disease, also known as primary adrenal insufficiency, is an endocrine condition involving destruction of parts of the adrenal gland (which sits atop...
Am Addisons Disease And Pregnancy

Addison’s Disease and Pregnancy

What are some implications for pregnancy with Addison’s disease? Among the many autoimmune diseases, Addison’s stands out as one with an often delayed...

Find more resources on autoimmunity

Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.